China’s Gan & Lee to Localize Insulin Production in Brazil via 10-Year Partnership
Gan & Lee Pharmaceuticals signs a landmark 10-year Technology Transfer and Supply Agreement with Fiocruz and Biomm to localize insulin glargine production in Brazil’s PDP program, securing ≥ RMB 3 billion in supply and boosting public health access.
On September 24, 2025, Gan & Lee Pharmaceuticals (603087.SH) announced a significant milestone in its international expansion: the signing of a 10-year Technology Transfer and Supply Agreement with Brazil’s Fundação Oswaldo Cruz (Fiocruz) and Biomm S.A., a leading Brazilian biopharmaceutical company. This collaboration is a pivotal component of Brazil’s Parcerias para o Desenvolvimento Produtivo (PDP) program, aimed at localizing the production of essential medicines to enhance public health resilience.
Strategic Collaboration to Address Brazil’s Insulin Supply Needs
The PDP program facilitates partnerships between Brazil’s public healthcare system and multinational pharmaceutical companies to transfer advanced manufacturing technologies, thereby establishing a self-sustaining domestic production ecosystem. In this context, Gan & Lee, Fiocruz, and Biomm have united to produce insulin glargine—a long-acting insulin essential for managing type 1 and type 2 diabetes—within Brazil.
Gan & Lee, leveraging over two decades of expertise in insulin research, development, and manufacturing, will transfer its insulin glargine technology to Fiocruz. Biomm will utilize this technology to produce insulin glargine at its facility in Nova Lima, Minas Gerais, ensuring compliance with local regulatory standards and facilitating rapid market entry. Fiocruz, as the ultimate purchaser under Brazil’s Health Regulatory Agency (Anvisa), commits to long-term procurement, adhering to agreed-upon prices and volume specifications.
This tripartite collaboration aims to significantly enhance the accessibility and affordability of high-quality insulin in Brazil, addressing the pressing public health need for a stable insulin supply.
Phased Implementation for Sustainable Local Production
The partnership is structured in three phases to achieve Brazil’s long-term goal of insulin self-sufficiency:
- Initial Phase: Gan & Lee will prioritize the supply of insulin glargine injection to meet urgent clinical demand in Brazil.
- Mid-Term Phase: Gan & Lee will transfer insulin glargine technology to Fiocruz, while continuing to supply both finished insulin glargine products and drug substances to Biomm. Biomm will conduct local filling of insulin glargine injection and deliver it, along with compatible pen injectors, to Fiocruz.
- Long-Term Phase: The three parties will collaborate in professional talent development and the establishment of full-scale quality control systems to ensure that locally produced insulin meets international standards of quality, safety, and efficacy, ultimately realizing Brazil’s goal of insulin self-sufficiency.
Financial Commitment and Strategic Impact
In conjunction with the Technology Transfer and Supply Agreement, Gan & Lee has entered into a Licensing and Supply Agreement with Biomm, securing cumulative orders of no less than RMB 3 billion (approximately USD 420 million) over the 10-year period. This substantial financial commitment underscores the strategic importance of the collaboration and aligns with Gan & Lee’s objectives to expand its global footprint and contribute to global healthcare governance.
This partnership not only strengthens Brazil’s pharmaceutical supply chain but also exemplifies a model of technological sharing under the Belt and Road Initiative, highlighting the potential for Chinese pharmaceutical enterprises to play a leading role in international public health cooperation.
Conclusion
The collaboration between Gan & Lee, Fiocruz, and Biomm marks a significant step toward enhancing Brazil’s self-sufficiency in insulin production and improving access to diabetes treatment for its population. By combining Gan & Lee’s advanced insulin technology with Biomm’s local manufacturing capabilities and Fiocruz’s regulatory expertise, this partnership sets a precedent for future public health collaborations between China and Brazil, contributing to the broader goal of global health equity.
Sources
Gan & Lee Pharmaceuticals Official Announcement:
https://www.ganlee.com/detail/801.html
Fiocruz Official Announcement (English):
https://fiocruz.br/en/news/2025/04/fiocruz-biomm-and-gan-lee-align-guidelines-national-production-insulin-glargine
Fiocruz Official Announcement (Portuguese):
https://fiocruz.br/noticia/2025/04/fiocruz-biomm-e-gan-lee-alinham-diretrizes-para-producao-nacional-da-insulina